Nature Reviews Gastroenterology & Hepatology

Article	Citations
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention	1072
The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	972
Advances in immunotherapy for hepatocellular carcinoma	764
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma	548
Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors	548
Dietary fibre in gastrointestinal health and disease	506
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	447
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments	441
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on fermented foods	422
Advancing the global public health agenda for NAFLD: a consensus statement	405
The gut microbiome as a modulator of healthy ageing	315
COVID-19 and liver disease: mechanistic and clinical perspectives	278
Evolving therapeutic landscape of advanced hepatocellular carcinoma	272
Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications	259
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests	250
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications	248
Potential intestinal infection and faecal–oral transmission of SARS-CoV-2	234
Global epidemiology of cirrhosis — aetiology, trends and predictions	232
The role of goblet cells and mucus in intestinal homeostasis	227
Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment	217
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer	216
AHR in the intestinal microenvironment: safeguarding barrier function	207
Therapeutic pipeline in nonalcoholic steatohepatitis	199
Role of liver sinusoidal endothelial cells in liver diseases	196
Current and future colorectal cancer screening strategies	195

Cirrhosis-associated immune dysfunction	193
Cell death in pancreatic cancer: from pathogenesis to therapy	191
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology	191
Global burden and epidemiology of Barrett oesophagus and oesophageal cancer	191
Paracellular permeability and tight junction regulation in gut health and disease	187
The intestinal barrier, an arbitrator turned provocateur in IBD	180
Hepatic inflammatory responses in liver fibrosis	175
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors	173
Liver ischaemia–reperfusion injury: a new understanding of the role of innate immunity	169
Gastrointestinal biofilms in health and disease	167
Global burden of hepatitis B virus: current status, missed opportunities and a call for action	163
Enteric glial biology, intercellular signalling and roles in gastrointestinal disease	163
Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma	160
Dietary carbohydrates and fats in nonalcoholic fatty liver disease	145
Current developments in gastric cancer: from molecular profiling to treatment strategy	142
Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders	135
The metabolic nature of inflammatory bowel diseases	133
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment	124
Leveraging diet to engineer the gut microbiome	123
Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure	122
Nonalcoholic fatty liver disease: another leap forward	116
Neutrophils as potential therapeutic targets in hepatocellular carcinoma	115
Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications	113
Disorders of the enteric nervous system — a holistic view	111
The pancreatic cancer genome revisited	111
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight	109
Breakthroughs in hepatitis C research: from discovery to cure	108
The role of oral bacteria in inflammatory bowel disease	103
COVID-19 and acute pancreatitis: examining the causality	103
Harnessing metabolic dependencies in pancreatic cancers	102
Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?	100
Revisiting fibrosis in inflammatory bowel disease: the gut thickens	99
Foundations of gastrointestinal-based drug delivery and future developments	96
Gut microbiota as a transducer of dietary cues to regulate host circadian rhythms and metabolism	95
Hippo signalling in the liver: role in development, regeneration and disease	92
Multiomics to elucidate inflammatory bowel disease risk factors and pathways	91
Recipient factors in faecal microbiota transplantation: one stool does not fit all	90
Gut–liver axis: barriers and functional circuits	90
Bench to bedside — new insights into the pathogenesis of necrotizing enterocolitis	88
Intra-pancreatic fat deposition: bringing hidden fat to the fore	88
Updated epidemiology of gastrointestinal cancers in East Asia	87
Early detection of pancreatic cancer using DNA-based molecular approaches	86
New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology	82
Understanding the physiology of human defaecation and disorders of continence and evacuation	82
Macrophages in intestinal homeostasis and inflammatory bowel disease	80
Lifestyle interventions in nonalcoholic fatty liver disease	80
Location is important: differentiation between ileal and colonic Crohn’s disease	79
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook	78
Defining comprehensive models of care for NAFLD	78
The promise of the gut microbiome as part of individualized treatment strategies	75

Current and emerging therapies for coeliac disease	74
Circadian clocks in the digestive system	73
Postbiotics — when simplification fails to clarify	73
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease	72
Human biomimetic liver microphysiology systems in drug development and precision medicine	70
The immune microenvironment in gastric adenocarcinoma	70
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease	68
The global burden of coeliac disease: opportunities and challenges	66
Gastrointestinal post-acute COVID-19 syndrome	65
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease	64
Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation	62
Bacteriophages and their potential for treatment of gastrointestinal diseases	62
Dietary management of adults with IBD — the emerging role of dietary therapy	61
Immunology and immunotherapy of cholangiocarcinoma	60
The scientific basis of combination therapy for chronic hepatitis B functional cure	58
Regulation and functional roles of chemokines in liver diseases	57
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology	57
Gut feelings: mechanosensing in the gastrointestinal tract	55
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease	53
Therapeutic developments in pancreatic cancer	53
Therapeutic landscape and future direction of metastatic colorectal cancer	51
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease	50
Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation	50
The war against pancreatic cancer in 2020 — advances on all fronts	49
Optimizing immunotherapy for colorectal cancer	49
Antibiotics in the pathogenesis of diabetes and inflammatory diseases of the gastrointestinal tract	48
IgG4-related diseases of the digestive tract	48
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management	47
Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease	47
Single-cell RNA sequencing in pancreatic cancer	46
Methanogenic archaea in the human gastrointestinal tract	45
The microbiota and the gut–liver axis in primary sclerosing cholangitis	45
Artificial intelligence and automation in endoscopy and surgery	38
Capturing the environment of the Clostridioides difficile infection cycle	38
SARS-CoV-2 vaccination in IBD: more pros than cons	35
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation	35
Extending treatment eligibility for chronic hepatitis B virus infection	34
Friend or foe? The elusive role of hepatic stellate cells in liver cancer	34
Nomenclature of HBV core protein-targeting antivirals	33
Machine perfusion of the liver: applications in transplantation and beyond	33
Mechanisms of pruritus in cholestasis: understanding and treating the itch	32
Exploring liver cancer biology through functional genetic screens	32
Hepatitis C virus elimination: laying the foundation for achieving 2030 targets	32
Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors	31
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach	29
Fermented foods and gastrointestinal health: underlying mechanisms	27
Improving IBD outcomes in the era of many treatment options	27
The gasdermin protein family: emerging roles in gastrointestinal health and disease	27
What are the clinical settings and outcomes of lean NAFLD?	27
A framework for fibrolamellar carcinoma research and clinical trials	26
Ultra-processed foods and food additives in gut health and disease	26
Nerves in gastrointestinal cancer: from mechanism to modulations	25
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer	25
Gene therapy for liver diseases — progress and challenges	25
Gastrointestinal and brain barriers: unlocking gates of communication across the microbiota–gut–brain axis	24
COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology	23
NAFLD, MAFLD and obesity: brothers in arms?	23
Modelling intestinal inflammation and infection using ‘mini-gut’ organoids	22
Author Correction: Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	22
Deciphering the different phases of preclinical inflammatory bowel disease	21
Human intestinal B cells in inflammatory diseases	21
Reply to: Postbiotics — when simplification fails to clarify	21
The maternal gut microbiome in pregnancy: implications for the developing immune system	21
Mycobiota–host immune interactions in IBD: coming out of the shadows	21
Benign liver tumours: understanding molecular physiology to adapt clinical management	21
Precision medicine in IBD: genes, drugs, bugs and omics	20
COVID-19 and liver disease: where are we now?	20
Environmental effects of surgical procedures and strategies for sustainable surgery	20
Inflammatory bowel disease in pregnancy and breastfeeding	20
Neutrophils: from IBD to the gut microbiota	19
Another renaissance for bile acid gastrointestinal microbiology	19
Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome	18
Advancing on pancreatic cancer	18
Secretory IgA: controlling the gut microbiota	18
A Roadmap for the Human Gut Cell Atlas	18
Cellular stress in the pathogenesis of nonalcoholic steatohepatitis and liver fibrosis	17
Author Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	17
Publisher Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	17
Genetics, pathobiology and therapeutic opportunities of polycystic liver disease	17
Natural history of NAFLD: knowns and unknowns	17

Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies	17
Mechanisms and pathophysiology of Barrett oesophagus	16
Environmental enteric dysfunction: gut and microbiota adaptation in pregnancy and infancy	16
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation	16
ChatGPT and large language models in gastroenterology	15
Deciphering potential implications of dietary microplastics for human health	15
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance	15
Commensal fungi in intestinal health and disease	14
Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology	14
Sex bias in clinical trials in gastroenterology and hepatology	14
Positioning therapies for the management of inflammatory bowel disease	14
Building gut from scratch — progress and update of intestinal tissue engineering	13
The tumour-associated microbiome	13
Intestinal gluconeogenesis: metabolic benefits make sense in the light of evolution	12
Demonstration of causality: back to cultures	12
Advances in the management of acute pancreatitis	12
Mechanisms and clinical management of eosinophilic oesophagitis: an overview	12
Novel insights into liver homeostasis and regeneration	12
The appendix and ulcerative colitis — an unsolved connection	11
Gut microbiota in overweight and obesity: crosstalk with adipose tissue	11
Standardized reporting of gastroenterology-related social media scholarship for career advancement	11
Digital biomarkers in human excreta	11
Re-examining chemically defined liquid diets through the lens of the microbiome	11
Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy	11
Reduction in colorectal cancer incidence by screening endoscopy	11
Guidelines for best practices in monitoring established coeliac disease in adult patients	10
Pursuing efficacious systemic therapy for hepatocellular carcinoma	10
Updates on systemic consequences of coeliac disease	10
Moving towards more patient-centred clinical trials in IBD	10
Rectally shed SARS-CoV-2 lacks infectivity: time to rethink faecal–oral transmission?	10
Scaling the immune incline in PDAC	9
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance	9
The International Network on Oesophageal Atresia (INoEA) consensus guidelines on the transition of patients with oesophageal atresia–tracheoesophageal fistula	9
Point-of-care intestinal ultrasonography in inflammatory bowel disease	9
Pathophysiology of gastro-oesophageal reflux disease: implications for diagnosis and management	9
Interrogating mechanisms of liver fibrosis with omics	9
Fetal liver development and implications for liver disease pathogenesis	9
Stigma: a major barrier to hepatitis B elimination	8
Ten steps to eliminating hepatitis C in hospitals	8
Lactylation and HCC progression	8
Digital pathology for nonalcoholic steatohepatitis assessment	8
Hepatic glucose metabolism in the steatotic liver	8
IBD risk prediction using multi-ethnic polygenic risk scores	8
Autism spectrum disorders and the gastrointestinal tract: insights into mechanisms and clinical relevance	8
Effects of dietary fibre on metabolic health and obesity	8
Cell senescence in liver diseases: pathological mechanism and theranostic opportunity	8
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice	7
Lenvatinib plus EGFR inhibition for liver cancer	7
Gut microbiome and autism spectrum disorder	7
Medical images, social media and consent	7
Sudden onset hepatitis in children	7
Glycogen phase separation and liver cancer	6
Future direction of total neoadjuvant therapy for locally advanced rectal cancer	6
Intercrypt goblet cells — the key to colonic mucus barrier function	6
The many means of conversation between the brain and the gut	6
Nifty new tools for microbiome treatment design	6
Tango of B cells with T cells in the making of secretory antibodies to gut bacteria	6
The gut microbiome in feast and famine	6
Tolerance-inducing therapies in coeliac disease — mechanisms, progress and future directions	6
Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases	6
Turning our focus to liver fibrosis	5
The current paradigm of bariatric surgery in adolescents	5
Reply to: Rectally shed SARS-CoV-2 lacks infectivity: time to rethink faecal–oral transmission?	5
Location, location, location — spatial insight into hepatic macrophage populations	5
Abdominal pain in irritable bowel syndrome	5
Innovations to improve the efficiency of phase II IBD clinical trials	5
Medical therapy of paediatric inflammatory bowel disease	5
Vaccination at the forefront of the fight against hepatitis B and C	5
Advancing alcohol-related liver disease: from novel biomarkers to refining selection for liver transplantation	5
Current status of colon capsule endoscopy in clinical practice	5
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions	5
Measuring NAFLD models of care	4
The war on pancreatic cancer: progress and promise	4
Mutations linked to chemotherapy resistance in colorectal cancer	4
Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards	4
Break the taboo with poo	4
PD1 blockade for advanced MSI-H CRC	4
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus	4
Origin of CAFs in colorectal cancer	4
Group 3 innate lymphoid cells in intestinal health and disease	4
Diversity, development and immunoregulation of enteric neurons	4
A single-cell view of biliary atresia	4
The path to successful hepatitis C elimination in Spain	4
Advancing health equity: The Association of Black Gastroenterologists and Hepatologists	4
Understanding HCC sex disparities	4
Author Correction: Current and future colorectal cancer screening strategies	4
Tirzepatide to treat obesity: phase III results	4
Gasdermin B in IBD and epithelial barrier repair	4
T cells in NASH and liver cancer: pathology and immunotherapy	4
Screening for liver fibrosis: lessons from colorectal and lung cancer screening	4
Pancreatic cancer: why the cell of origin matters	4
Envisioning how to advance the MASH field	4
Full-spectrum transcriptomics in NAFLD	4
Molecular landscape of NASH-HCC	4
E. faecalis promotes liver carcinogenesis	4